TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Lupin Limited ( (IN:LUPIN) ) is now available.
Lupin Limited’s subsidiary, Nanomi B.V., has entered into a definitive agreement to acquire VISUfarma B.V., a specialty pharmaceutical company based in Amsterdam, Netherlands. VISUfarma focuses on ophthalmology and has a significant commercial presence across major European countries, offering products for dry eye, glaucoma, and other eye-related conditions. This acquisition is expected to enhance Lupin’s market positioning in the European ophthalmology sector, potentially expanding its product offerings and market reach.
More about Lupin Limited
Lupin Limited is a company operating in the pharmaceutical industry, with a focus on developing and distributing a wide range of pharmaceutical products. The company has a global presence and is involved in the production of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients.
Average Trading Volume: 22,150
Technical Sentiment Signal: Buy
Current Market Cap: 877.3B INR
Find detailed analytics on LUPIN stock on TipRanks’ Stock Analysis page.